Torrent Pharmaceuticals 

Torrent Pharmaceuticals is the listed flagship of the Torrent Group and a finished-dose and specialty-medicine company whose core work is developing, manufacturing, and marketing prescription and branded generic therapies for India and regulated export markets. It is not a neighbourhood chemist chain, not a contract-research boutique, and not a single-molecule startup. The franchise traces to U.N. Mehta’s work in the 1970s and to a deliberate niche-marketing model that built share in cardiology, central-nervous-system, gastro, and other specialty desks rather than only commodity volume. For FY2026 the company has reported turnover of about ₹13,980 crore. A doctor who prescribes a Torrent brand, or a patient who fills that script, is still dealing with the same legal entity that files results, runs plants, and holds the marketing authorisations. The product map is specialty-led and geographically wide. India remains the home book. Exports reach more than fifty countries. In Brazil and Germany the company has described itself as holding the number-one share among Indian pharmaceutical companies in those markets—an export fact, not a claim to be the largest local originator. Manufacturing, quality systems, and field-force coverage sit beside that book so the franchise is not only a marketing story. Niche marketing—focused therapies, specialist detailing, and brand building—is still how Torrent explains its competitive method versus broad unbranded generics houses. Governance and disclosure follow listed-company and drug-regulator practice. Indications, prescribing information, pharmacovigilance contacts, plant addresses, and audited numbers belong on Torrent Pharmaceuticals’ own website, on pack inserts, and in exchange filings, not in a social caption. Official social destinations—Facebook at TorrentPharmaceuticalsLimited, LinkedIn at /company/torrent-pharmaceuticals-ltd, and X at @torrentpharmaIn—are brand and public-information channels. They publish results headlines, therapy-awareness films, factory and CSR colour, and employer news. They are not pharmacies, not prescription desks, and not places to buy scheduled medicines or send payment for a “special import.” Impersonation of pharma brands is common; treat any message that asks for remote access, Aadhaar images, or payment for medicines off a licensed chemist invoice as fraud. English is the corporate language of investor and medical communication; Hindi and regional creative appear on awareness campaigns. Country for these listings is India. Follow only the official handles listed here. Confirm labels, adverse-event reporting, and audited numbers on the company website and in filings, then treat every post as communication from a full-line listed pharma company whose commercial fact is the Torrent Group flagship, a 1970s U.N. Mehta origin, niche marketing, FY2026 turnover of about ₹13,980 crore, presence in fifty-plus countries, and leading Indian-company share in Brazil and Germany.